18/12/2025
๐ฟ ๐๐ฅ๐จ๐๐๐ฅ ๐๐ฎ๐ญ๐ซ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐๐๐๐ ๐๐๐ซ๐ค๐๐ญ
The global Nutraceutical CDMO (Contract Development & Manufacturing Organization) Market is projected to grow from US$ 40.2 billion in 2025 to US$ 68.9 billion by 2032 at a CAGR of 8%, driven by rising preventive healthcare demand and increasing outsourcing among nutraceutical companies.
๐๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ ๐ญ๐ก๐ ๐
๐ฎ๐ฅ๐ฅ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.fairfieldmarketresearch.com/report/nutraceutical-cdmo-market
๐๐จ๐ฌ๐๐ ๐ ๐
๐จ๐ซ๐ฆ๐ฌ ๐๐๐๐๐ข๐ง๐ ๐ญ๐ก๐ ๐๐๐ฒ
Tablets & Capsules dominate with ~40% share, thanks to consumer familiarity and mature manufacturing processes. Powders are gaining traction for functional beverages and personalized nutrition, reflecting the shift toward clean-label and plant-based products.
๐๐ข๐ ๐ก-๐๐๐ฆ๐๐ง๐ ๐๐๐ซ๐ฏ๐ข๐๐๐ฌ
Manufacturing & Packaging leads with ~35% share, as mid-sized companies increasingly outsource production to access advanced facilities and cost efficiencies. Formulation development, analytical testing, and regulatory support are growing fast, especially for CDMOs with strong R&D capabilities.
๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ
Asia-Pacific: Fastest-growing, led by Chinaโs manufacturing ecosystem and Indiaโs role in global botanical ingredient sourcing.
North America: Largest market (~40% share), supported by FDA-regulated quality systems and market maturity.
Europe: Growth supported by regulatory harmonization, specialized CDMOs, and emerging ESG priorities.
๐๐๐๐๐ข๐ง๐ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ include Catalent Inc., Lonza Group, Nutrascience Labs, Robinson Pharma, and Aenova Group, demonstrating a mix of global scale and specialized expertise.
The Nutraceutical CDMO Market is a hub of innovation, growth, and opportunities for companies ready to scale and deliver next-generation health solutions.